Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Sigulda – page 7

116 clinical trials in Sigulda, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Sigulda at a glance
116
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

116 trials in Sigulda

Open in trial search

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Embolism venous

Not recruiting

Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Sirius Therapeutics Inc.

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Bladder cancer

Not recruiting

Study on UGN-102 (Mitomycin) for Treating Low Grade Non-Muscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Poloxamer 407
  • Sponsor:Urogen Pharma Ltd.

Abdominal infection+3

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Urinary tract infection+1

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Meiji Seika Pharma Co. Ltd.

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Sigulda

What the registry says about research in the country

01 Diabetes Research

Clinical investigations focusing on advancing treatment options for patients with Type 2 Diabetes who aren't achieving optimal control with current medications.

  • Therapeutic Focus: Blood glucose management
  • Treatment Combination Studies
  • Metabolic Disease Research

The research evaluates the effectiveness of combining gliclazide MR with existing diabetes medications to improve glycemic control, particularly focusing on HbA1c reduction in patients with inadequate response to current treatments.

02 Metabolic Disorders

Innovative research exploring combination therapy approaches in metabolic disease management, specifically targeting patients with suboptimal response to standard treatments.

  • Medication Optimization
  • Glycemic Control Studies
  • Treatment Enhancement Research

This clinical investigation aims to advance our understanding of treatment optimization for patients requiring additional therapeutic support beyond initial medication regimens.

03 Treatment Efficacy

Comprehensive evaluation of treatment effectiveness in diabetes management, focusing on medication combinations to achieve better patient outcomes.

  • Safety Assessment
  • Clinical Response Monitoring
  • Long-term Effectiveness

The research examines both the efficacy and safety profiles of combined therapeutic approaches over a 24-week period, providing valuable insights into treatment optimization strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.